➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
Express Scripts
Merck
Colorcon

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GSK2256294

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GSK2256294?

GSK2256294 is an investigational drug.

There have been 5 clinical trials for GSK2256294. The most recent clinical trial was a Phase 1 trial, which was initiated on May 17th 2018.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, and Chronic Disease. The leading clinical trial sponsors are GlaxoSmithKline, Vanderbilt University Medical Center, and Oregon Health and Science University.

There are two US patents protecting this investigational drug and thirty-one international patents.

Recent Clinical Trials for GSK2256294
TitleSponsorPhase
Soluble Epoxide Hydrolase Inhibition and Insulin ResistanceVanderbilt University Medical CenterPhase 2
Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition TrialOregon Health and Science UniversityPhase 1/Phase 2
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic ConditionsParexelPhase 1

See all GSK2256294 clinical trials

Clinical Trial Summary for GSK2256294

Top disease conditions for GSK2256294
Top clinical trial sponsors for GSK2256294

See all GSK2256294 clinical trials

US Patents for GSK2256294

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GSK2256294   Start Trial sEH inhibitors and their use GlaxoSmithKline, LLC (Philadelphia, PA)   Start Trial
GSK2256294   Start Trial sEH inhibitors and their use GlaxoSmithKline LLC. (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GSK2256294

Drugname Country Document Number Estimated Expiration Related US Patent
GSK2256294 Australia 2008310732 2027-10-11   Start Trial
GSK2256294 Brazil PI0817542 2027-10-11   Start Trial
GSK2256294 Canada 2702265 2027-10-11   Start Trial
GSK2256294 China 101896065 2027-10-11   Start Trial
GSK2256294 Colombia 6270285 2027-10-11   Start Trial
GSK2256294 Costa Rica 11423 2027-10-11   Start Trial
GSK2256294 Cyprus 1114865 2027-10-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
Express Scripts
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.